Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[Zr-89]Oxinate-4-labeled Leukocytes in Central Inflammatory Disorders
NCT03807973Phase 1Suspended
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 2021
- Primary completion
- Oct 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of zirconium-89 oxine-labeled leukocytes in fibromyalgia (FM), myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS) and multiple sclerosis (MS) (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Regional brain distribution of radiolabeled white blood cells at 3 years. Started Oct 2021; status: suspended.
02
Drugs
zirconium-89 oxine-labeled leukocytes
03
Conditions
fibromyalgia (FM)myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03807973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807973.